Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Conditions
Primary Liver Cancer
Conditions: official terms
Carcinoma, Hepatocellular - Liver Neoplasms
Conditions: Keywords
Primary liver cancer
Study Type
Interventional
Study Phase
Phase 1
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Intervention
Name: MRI of the liver before start of treatment Type: Procedure
Name: MRI after treatment Type: Procedure
Name: PET-scan before treatment start Type: Procedure
Name: PET scan after treatment Type: Procedure
Overall Status
Recruiting
Summary
Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this response. Often it takes several months for anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early indicator of response. This "early" information might help to tailor treatment. For instance, if no response is induced, an early switch in therapy can be planned.

The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with inoperable primary liver cancer is treated (radionuclide therapy, biologicals).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria :

- Male and female are eligible

->18years of age.No upper age limit.

- not pregnant or breastfeeding

- capable of understanding the study goals and protocol and to sign the informed consent.

- Patients are diagnosed with primary liver cancer and referred for treatment with biologicals such as Sorafenib or treatment with radionuclides.
Location
University Hospital Ghent
Ghent, Belgium
Status: Recruiting
Start Date
May 2010
Completion Date
October 2015
Sponsors
University Hospital, Ghent
Source
University Hospital, Ghent
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page